Sentences with phrase «generic drugs at»

Many large retailers, such as Target, Walmart, and Kmart, offer hundreds of types of generic drugs at substantial discounts.

Merritt cited a backlog among approval for generic drugs at the FDA as one of the reasons that many drugs don't face generic competition just yet.

Prices for roughly 300 generic drugs at least doubled from 2010 to 2015.

Not exact matches

For one thing, «There are a lot of good drugs on the market for heart disease right now that come in generic form,» says Neil Lesser, a principal at Deloitte who specializes in the life sciences, in an interview with Fortune.

Rajiv Malik, president and executive director at EpiPen maker Mylan (essentially the company's number two exec), has been named in a wide - ranging civil suit alleging drug price collusion by numerous prominent generic drug makers.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Plus, a handful of companies will typically all get approved to make a generic at once, which ideally creates competition in the marketplace and can sometimes result in even lower prices for those drugs.

Daiichi Sankyo's press release comes in the wake not only of Ranbaxy's highly unusual criminal guilty plea and $ 500 million in fines and penalties — the largest ever against a generic - drug maker — but also a lengthy Fortune article that exposed for the first time the depth and extent of the fraud charges leveled at the company and the knowledge of senior company executives.

The epic inside story of long - term criminal fraud at Ranbaxy, the Indian drug company that makes generic Lipitor for millions of Americans.

The companies have begun to market their «biosimilar» (a generic version of expensive biologic drugs) of Remicade — a copycat of J&J's best - selling rheumatoid arthritis and immunology treatment (which garnered more than $ 5 billion in U.S. sales last year) and was approved by the Food and Drug Administration (FDA) in April — at a striking 35 % discount to its list price.

While the drug maker has responded to the massive backlash over its extravagant price increase on the device by boosting its patient assistance programs and introducing an authorized generic EpiPen version at half the cost, CVS» topline price will still be significantly cheaper.

Still, he's taken on market inefficiencies, called for expanding access to biosimilars, is approving generics at a record pace and trying to bring down drug prices.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

After graduating from the University of Calcutta in 1982, Dilip Shanghvi started working at his father's wholesale generic - drugs business, where he saw an opportunity to manufacture Lithosun, a drug that treated manic - depressive disorders and was unavailable in much of eastern India.

Provincial governments, strapped for cash and facing ballooning deficits, have been hacking away at the prices they pay for generic drugs.

Akorn — German drugmaker Fresenius pulled out its $ 4.75 billion deal to buy the U.S. generic drugmaker, saying it had found «material breaches» of Food and Drug Administration data integrity requirements at Akorn.

Fresenius (FMS) pulled out its $ 4.75 billion deal to buy U.S. generic drug - maker Akorn (AKRX), saying it had found «material breaches» of FDA data integrity requirements at Akorn, which disputes those claims.

Israel - based Teva, the world's largest maker of generic drugs, has been looking at divestures to help pare its $ 35 billion debt pile.

Once a drug loses its patents, generic drug manufacturers start selling copycat versions at substantially lower prices.

Stada's owners are also mulling bids for the generic drug business being sold by Sanofi, the sources said, and might favor this combination over Merck as generic drugs are typically valued at a cheaper multiple.

The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale.

The solanezumab disappointment comes at a time when Lilly is facing generic competition on several high - profile drugs, including erectile dysfunction medicine Cialis, ADHD drug Strattera and cardiovascular treatment Effient.

Zytiga's future is murkier than the other two drugs because Zytiga's patent protection is expiring later this year and that may lead to the launch of generic drugs that begin to chip away at its market share.

Court documents made public late on Tuesday show that Fresenius (NYSE: FMS) dropped its acquisition of Akorn after uncovering evidence that the generic drug developer submitted fraudulent data to the U.S. Food and Drug Administration for at least six different drugs dating back to 2drug developer submitted fraudulent data to the U.S. Food and Drug Administration for at least six different drugs dating back to 2Drug Administration for at least six different drugs dating back to 2012.

As long as that strategy continues to control the decline in Remicade's sales, then growth from these drugs should offset any drop — at least until J&J has to deal with a generic Zytiga.

The U.S. Food and Drug Administration's approval of Mylan N.V. (NASDAQ: MYL)'s generic version of Copaxone for the treatment of relapsing multiple sclerosis should be seen as a «clear negative» for Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s Glatopa franchise, analysts at Baird said.

** German healthcare group Fresenius SE said it had decided to pull out of its planned acquisition of Akorn after it found data integrity breaches at the U.S. generic drug maker.

BERLIN German healthcare group Fresenius SE said it had decided to pull out of its planned acquisition of Akorn after it found data integrity breaches at the U.S. generic drug maker.

This prevented developing countries from producing generic versions of patented drugs, notably treatments for HIV / AIDS and malaria, which they maintained were being sold at unfair prices.

They estimate that generic - drug manufacturers should be able to produce the pills at $ 100 — 250 for a 12 - week course.

Dr Bokhari said: «The drug companies argue that they have a right to protect their intellectual property and that these agreements benefit consumers by enabling generic versions to come onto the market sooner than they would normally have, for example if licensed entry has been allowed at a later date but before the patent expires.

For example, sofosbuvir's manufacturer, Gilead Sciences Inc. of Foster City, California, sells the drug to Egypt at a discount and allows generic manufacturers in India to produce and sell in 91 poorer countries.

The study included 35 patients, adults with epilepsy who currently take lamotrigine, and looked at long - term dosing using two currently on - market epileptic generic drugs.

The generic risperidone products will have the same safety warnings as Risperdal, including a boxed warning, cautioning that older patients with dementia - related psychosis treated with atypical anti-psychotic drugs are at increased risk of death, as compared with those taking placebo.

Oseltamivir, a generic form of the oral antiviral drug Tamiflu, received FDA approval at the end of last summer, and both it and an inhaled antiviral, zanamivir (aka Relenza) are available by prescription this season.

We don't very often see [that] the generic drug that's available at your drugstore anyways might have some use for cancer.»

That collection belonged to Marvin Schein, a manufacturer and distributor of generic drugs and medical products from Long Island who had spent years quietly buying paintings, porcelains and French furniture, many of them at auction.

The firm undertook an analysis of data in the FDA's Adverse Event Reporting System related to the stomach disorder drug, and «identified at least 106 cases of tardive dyskinesia or other movement disorders reported among users of Reglan or its generic version, metoclopramide.»

Represented Braintree Laboratories at the Federal Circuit to reverse a district court's grant of summary judgment of noninfringement for Breckenridge Pharmaceutical, following a patent dispute concerning Breckenridge's planned generic version of Braintree's SUPREP laxative drug.

The Jean Coutu Group were facing several challenges at the time including drug distribution reform and the purchase of a Quebec generic drug manufacturer.

While pharmaceutical giant Pfizer is trying to get the Supreme Court of Canada to take a second look at its recent judgment voiding its patent on Viagra, it's trying to use the same decision to quash a case in the Federal Court involving another generic drug maker.

At issue is whether the Supreme Court should reinforce its 2011 ruling that protected generic drug manufacturers from state products liability claims accusing them of not warning about possibly dangerous side effects.

Our pharmaceutical work puts us at the forefront of cutting edge issues, including preemption of medical device and prescription drug claims, the learned intermediary doctrine, comment k, market share liability, and brand name liability for generic use.

Whether or not it was envisioned at the time, the use of generic drugs in the US has seen a tremendous increase since the enactment of the Act.

Pfizer sells about 600 generic medicines, including at least 40 that it made a deal for this week that it will sell in the United States; and Teva now reportedly gets about 30 % of its revenue from branded drugs.

[10] Prior to 2006, the price at which manufacturers could apply to list generic drugs in the Formulary was capped by regulations under the Actsat effectively 63 % of the price of the brand - name drug.

«Any recognition of an outlier theory of liability permitting a generic drug consumer to bring an action against the brand manufacturer for an injury allegedly arising from the use of the generic drug would be plainly at odds with this public policy.»

If your employees take prescription drugs, check the cost of both generic and brand drugs at the pharmacy.

Optional prescription drug benefits up to $ 5,000 per insured per policy period (100 % after a $ 10 copay for generics, name brand prescriptions require a $ 25 copay and injectibles are covered at 70 %).

Or what about which prescription drugs your plan covers, and which are generic - or not covered at all?